Mystic granted patent for drug-delivery tech; Dry powder nasal sprays a 'hot topic';

> Mystic Pharmaceuticals, based in Austin, TX, has been granted a new patent for drug and biologic delivery technology, key to its VersiDoser and VRx2 systems. The technology involves preservative free dose packaging and devices for applying ophthalmic and intranasal drugs. Story

> Unilife, a York, PA-based medical device company, says one of its technologies has been chosen as the delivery device for a biologic drug in an upcoming clinical trial, but will not reveal any more. In-PharmaTechnologist says the deal "is good news for Unilife which has struggled in recent quarters." Story

> Looking for partners: a company that has developed "an innovative frozen lozenge technology designed to deliver pharmaceuticals and OTC products" for pediatrics and difficult-to-swallow therapeutics. More here

> Dry powder nasal sprays a "hot topic" at the Respiratory Drug Delivery Europe 2011 conference in Berlin. Release

> Everything you need to know about polymers in drug-delivery systems. Educational site

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.